



Published in final edited form as:

Int J Cardiol. 2016 June 01; 212: 1–10. doi:10.1016/j.ijcard.2016.03.001.

Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement

Simon Stewart^{a,*}, Barbara Riegel^b, Cynthia Boyd^c, Yasmin Ahamed^d, David R. Thompson^e, Louise M. Burrell^f, Melinda J. Carrington^g, Andrew Coats^h, Bradi B. Grangerⁱ, Julie Hides^j, William S. Weintraub^k, Debra K. Moser^l, Victoria Vaughan Dickson^m, Cressida J. McDermott^d, Ashley K. Keates^d, and Michael W. Richⁿ

^aMary MacKillop Institute for Health Research Centre of Research Excellence in Health Service Research to Reduce Inequality in Heart Disease, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, Victoria 3000, Australia

^bUniversity of Pennsylvania School of Nursing, Room 335 Fagin Hall, 418 Curie Blvd., Philadelphia, PA 19104-4217, USA

^cCenter on Aging and Health, John Hopkins University, Mason F. Lord Building, 7th Floor, Center Tower, 5200 Eastern Avenue, Baltimore, MD 21224, USA

^dMary MacKillop Institute for Health Research, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, Victoria 3000, Australia

^eMary MacKillop Institute for Health Research, Centre for the Heart and Mind, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, Victoria 3000, Australia

^fThe University of Melbourne, Department of Medicine, Austin Health, Level 7, Room 10, Lance Townsend Building, Austin Health, Heidelberg, Victoria 3084, Melbourne, Australia

^gMary MacKillop Institute for Health Research, Centre for Primary Care and Prevention, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, Victoria 3000, Australia

^hMonash and Warwick Universities, Monash Warwick Alliance Office, Building 3A, Clayton Campus, Wellington Road, Victoria 3800, Australia

ⁱDuke University School of Nursing, 307 Trent Drive, Durham, NC, 27710, USA

^jMary MacKillop Institute for Health Research, Centre for Musculoskeletal Research, Australian Catholic University, Level 1, 631 Stanley Street, Woolloongabba, Queensland 4102, Australia

^kJefferson University, Christiana Care Health Services, Center for Heart & Vascular Health, Suite 1070, 4755 Ogletown-Stanton Road, Newark, DE 19713, USA

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

*Corresponding author at: Mary MacKillop Institute for Health Research, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, Victoria 3000, Australia.

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.ijcard.2016.03.001>.

^lUniversity of Kentucky, Center for Biobehavioral Research in Self-Management of Cardiopulmonary Diseases, College of Nursing, 527 College of Nursing Building, Lexington, KY 40536-0232, USA

^mNew York University, College of Nursing, 433 First Ave Room 742, New York, NY 10010, USA

ⁿWashington University School of Medicine, Cardiovascular Division, 660 S. Euclid Ave, Campus Box 8086, St. Louis, MO 63110, USA

Abstract

Background—Multimorbidity in heart failure (HF), defined as HF of any aetiology and multiple concurrent conditions that require active management, represents an emerging problem within the ageing HF patient population worldwide.

Methods—To inform this position paper, we performed: 1) an initial review of the literature identifying the ten most common conditions, other than hypertension and ischaemic heart disease, complicating the management of HF (anaemia, arrhythmias, cognitive dysfunction, depression, diabetes, musculoskeletal disorders, renal dysfunction, respiratory disease, sleep disorders and thyroid disease) and then 2) a review of the published literature describing the association between HF with each of the ten conditions. From these data we describe a clinical framework, comprising five key steps, to potentially improve historically poor health outcomes in this patient population.

Results—We identified five key steps (ARISE-HF) that could potentially improve clinical outcomes if applied in a systematic manner: 1) *Acknowledge* multimorbidity as a clinical syndrome that is associated with poor health outcomes, 2) *Routinely* profile (using a standardised protocol — adapted to the local health care system) all patients hospitalised with HF to determine the extent of concurrent multimorbidity, 3) *Identify* individualised priorities and person-centred goals based on the extent and nature of multimorbidity, 4) *Support* individualised, home-based, multidisciplinary, case management to supplement standard HF management, and 5) *Evaluate* health outcomes well beyond acute hospitalisation and encompass all-cause events and a person-centred perspective in affected individuals.

Conclusions—We propose ARISE-HF as a framework for improving typically poor health outcomes in those affected by multimorbidity in HF.

Keywords

Heart failure; Multimorbidity; Person-centred perspective; Multidisciplinary management

1. Introduction

Those with multimorbidity are an emerging patient population that is challenging health care systems worldwide. For example, almost half of all US adults live with one chronic illness [1] and multimorbidity is increasing as the population ages [2]. Accordingly, recent estimates suggest that two-thirds of US Medicare beneficiaries (close to 21 million patients) have two or more chronic conditions and more than one-third have four or more [3,4]. Similarly, in Australia and Europe, a quarter of the population has multimorbidity, with prevalence and complexity increasing with age: 83%, 58% and 33% of patients aged 75

years or older have at least two, three or four concurrent conditions, respectively, requiring active management [5,6]. Unsurprisingly, multimorbidity is not a benign phenomenon. The risk of hospitalisation, re-hospitalisation, and death rise as the number of chronic conditions increases [7].

Multimorbidity is common in patients with heart failure (HF), increasing their risk for poor health outcomes. Lone HF is rare and is exceedingly rare in the predominant HF patient population aged 75 years and older [8]. In the US, approximately 40% of Medicare beneficiaries with HF have >5 non-cardiac conditions and this group accounts for >80% of the total inpatient HF-related hospital days in the US [9]. Annual total costs for HF are expected to more than double between 2012 and 2030 (\$31 billion to \$70 billion USD) [10] making HF the foremost contributor to Medicare expenditures [11]. The majority (61%) of hospital readmissions are attributable to multimorbidity [12], and occur within 15-days of discharge [13]. About half of all hospitalisations in HF patients are thought to be preventable [9]. This is particularly problematic in those with HF and preserved ejection fraction, for whom multimorbidity is the major driver of hospitalisations. To date, authors of expert guidelines have struggled to address the issue of multimorbidity in HF and articulate clear pathways to optimise health outcomes. Not surprisingly, however, there has been increasing interest in providing clinicians and health care teams with more guidance to improve the management of HF in the context of multimorbidity [14].

2. Aims

We recognise the complex clinical challenges inherent to managing HF in the setting of multimorbidity and the limitations of practice guidelines in providing a comprehensive overview of the applicability of treatment options. Thus, the specific aims of this position paper (from an international, multidisciplinary panel of health professionals with an ongoing interest and expertise in HF management) are two-fold:

1. To provide a comprehensive overview of the current literature focussing on the most common conditions requiring concurrent treatment and management in patients with HF.
2. To articulate a practical framework for establishing a systematic response to this increasingly common clinical phenomenon that has the potential to improve health outcomes.

We explicitly recognise that the practical steps outlined in this document are yet to be proven in terms of improved health outcomes (indeed they form the basis for a proposed, international, multicentre trial). However, we propose that these steps be used (in part or in their entirety) to inform and complement contemporary guidelines to improve health outcomes in those affected by HF and multimorbidity, regardless of the health care system in which they are managed.

3. Literature review

We began by surveying the literature, noting a contemporary study of multimorbidity in the HF patient population [15,16]; we identified the ten most prevalent concurrent conditions in

HF (other than hypertension and ischaemic heart disease) requiring concurrent management. The ten most prevalent conditions (other coronary disease and hypertension) identified in the literature were anaemia, sleep disordered breathing, respiratory disease, Type 2 diabetes, depression, renal impairment, cognitive impairment, musculoskeletal disorders, arrhythmias, and thyroid disease. This list was then validated in two large patient cohorts (>1000 patients) in Australia and the USA via purposeful profiling (comprising detailed psychosocial and clinical phenotyping) of typically older patients with HF at the time of hospital discharge. Whilst we acknowledge this may not represent the definitive “top ten” list of concurrent conditions in HF (indeed we considered a number of other potential conditions of interest) in all settings, we largely focus on our validated list. These conditions are often closely linked, occur concomitantly, and represent natural targets for better management from a multimorbidity perspective due to the typical clinical “conundrum” they represent — see Fig. 1: A conundrum of multimorbidity in HF (reproduced with permission) [15]. As depicted in Fig. 1, the patterns of interaction in multimorbidity present an opportunity to prospectively manage predictable gaps in patient care, such as polypharmacy, care coordination, and communication among multidisciplinary providers.

Focussing on these ten pre-specified conditions, we then searched the literature (using the specific search terms outlined in Table 1) to identify publications focused on the management of these conditions in the setting of HF. Specifically, the search was performed using Medline and was limited to reports published during the period 2005 to 2015, in order to capture the most up-to-date literature. Ten individual searches were conducted in which the specific co-morbidity of interest, along with HF, and their combined management or treatment was entered into Medline. This yielded a total of 3573 citations, which were then reviewed for relevancy — see Table 1. The full text articles were reviewed and a tabulated summary of extracted information from 194 papers is provided in Supplementary Table 1.

The literature reviewed using this search strategy and subsequent data extraction (noting the often fragmented approach to examining multimorbid conditions in HF) was contextualised according to the authors’ own experiences in managing large numbers of older patients (i.e. those aged 75 years or more) with HF and multimorbidity. A pragmatic clinical framework, ARISE-HF, (comprising a series of five key steps — see text box below) to frame clinical practice, research, and future health policy was initially drafted by SS and BR and subsequently circulated for review, revision and approval by the group.

ARISE-HF

A = Acknowledge multimorbidity as a clinical syndrome that is associated with poor health outcomes

R = Routinely profile (using a standardised protocol - adapted to the local health care system) all patients hospitalised with HF to determine the extent of concurrent multimorbidity

I = Identify individualised priorities and person-centred goals based on the extent and nature of multimorbidity

S = Support individualised, home-based, multidisciplinary, case management to supplement standard HF management

E = Evaluate health outcomes well beyond acute hospitalisation and encompass all-cause events

The section below expands upon the ARISE-HF framework and how it might be applied on a systematic basis.

4. A step-wise approach to improve health outcomes (ARISE-HF)

4.1. Step 1: Acknowledge multimorbidity as a clinical syndrome associated with poor health outcomes

As previously noted by Tinetti and colleagues [17], multimorbidity in HF has emerged as a clinical syndrome associated with poor health outcomes. Based on our review of the literature (see below), it is reasonable to classify HF with concomitant multimorbidity as a distinct clinical syndrome in order to provoke a more systematic response from the health care system. For example, it is of particular concern that HF patients with a high burden of multimorbidity living in low-income areas are at increased risk for all-cause re-hospitalisation, suggesting that illness burden may influence the association between income and outcomes in these patients [18]. In contrast to an increasing recognition that specific clusters of conditions are associated with extended length of hospital stay, elevated cost, and increased risk of mortality [19], the current literature is largely fragmented, focussing on common clinical dyads (e.g. HF and diabetes) and framing clinical management in isolation from other complicating factors (e.g. renal dysfunction). Supplementary Table 1 summarises key clinical issues for each condition of interest.

4.2. Step 2: Routinely profile (using a standardised protocol) patients with HF to determine the extent of concurrent multimorbidity

A logical extension to recognising multimorbidity in HF as a clinical syndrome requiring a coordinated clinical response is to identify which patients (particularly those at high risk of related poor health outcomes) are affected by what condition. As such, we recommend all older patients admitted to hospital with HF should be systematically profiled for multimorbidity in order to optimise care. At minimum, this would include the ten common conditions identified that complicate HF management (other than routinely diagnosed and managed coronary artery disease and hypertension) with consideration of other potential conditions according to the patients clinical profile. In the presence of multiple admissions/clinical instability, it would be reasonable to review the extent and progression of multimorbidity on a regular basis. Findings should be noted in the clinical records and included as part of any communication with the patient's wider health care team. Advanced electronic health records (EHR) and informatics would facilitate both the identification and tracking of such individuals. However, EHR capacity is highly variable across different health systems. It is also important to note that any protocol for managing patient's with HF and multimorbidity will likely rely on a component of "routine" profiling (e.g. review of prior records and standard review of electronic systems) as well as an active component of profiling (e.g., to determine cognitive function). Although profiling focusses on hospitalised individuals, there is a clear need to consider when it is best and most reliable to perform profiling; ideally when the individual is clinically stable and, in some cases, post hospital discharge. The latter in particular requires clear lines of communication with the primary health care team. Table 2 summarises the definitions and methods that might be routinely applied to identify ten common comorbid conditions in HF (i.e. those conditions of particular interest to this position paper).

4.3. Step 3: Identify individualised priorities and person-centred goals based on the extent and nature of multimorbidity

As shown in Supplementary Table 1, there are potentially many competing priorities arising from multimorbidity in HF that are not easily addressed in a generic manner — hence the historical difficulty for guideline committees to provide specific recommendations in the setting of marginal benefit-risk ratios. For example, there has been a reluctance to prescribe high doses of neurohormonal/vasodilator therapy in the setting of frailty and high risk of falls and/or evidence of progressive renal dysfunction despite the potential benefits [20,21]. On this basis, we suggest a structured approach that considers the nature and severity of multimorbidity, defines an individualised list of clinical priorities and identifies the need for specialist consultation when appropriate. Critically, as part of a patient-centred approach, patient preferences and goals regarding their own health [22], as well as conflicting and contraindicated treatment options should play a prominent role in the decision points of the algorithm. This requires a truly multidisciplinary, team-based approach to management [23] that provides the patient and their caregivers with the knowledge to foster better care and to provide advice on their options pertaining to their treatment and management. Whilst we have suggested a clear focus on the hospitalised patient (with the opportunity to complete most if not all components of screening for multimorbidity), it is clear that subsequent management will be applied within the community/out-patient setting. A suitably qualified health professional (such as an experienced nurse with relevant qualifications) has the capacity to generate realistic and achievable care/action plans when — a) consulting and assessing patients in their home and then b) consulting with the wider health care team to determine what can be done to meet the patient’s needs [24–26].

4.4. Step 4: Support individualised, home-based, multidisciplinary, case management to supplement standard HF management

As recently articulated in the AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients with Cardiovascular Disease and Comorbid Conditions [27], there is a compelling imperative to adjust management strategies in the setting of multimorbidity, and standard HF management is no exception. Beyond recognising and characterising multimorbidity (see recommendations 1–3), strategic plans that are robust (i.e., can be applied in different health care systems with variable personnel, capacity and resources), flexible, feasible, cost-effective and focused on addressing each problem in the broader context need to be formulated.

4.4.1. Management options—Disease management has demonstrated benefit for improving clinical outcomes. In the last two decades, a variety of robust HF disease management approaches have been developed and tested, aimed at improving HF outcomes and reducing hospitalisations [26,28–31]. Numerous meta-analyses have documented the effectiveness of disease management programmes for HF [32–40]. However, implementation of these programmes in clinical practice is highly variable. This is reflected in a recent study confirming wide variation in the care provided to HF patients after discharge from the hospital [41]. A pooled analysis of ten HF disease management RCTs highlighted that the essential components of these programmes in reducing the number and length of hospital

admissions were multidisciplinary, team-based care that included in-person communication between case managers, physicians and patients [42].

It is notable that much of the evidence-base supporting HF disease management programmes, for both historical and practical reasons, has been primarily focused on relatively less complex cases, and thus is less applicable to the population with HF and multimorbidity. Yet, epidemiological data show that patients hospitalised with HF are becoming increasingly older (with associated multimorbidity rising at the same time) [43–45]. Accordingly, more contemporary clinical trials of HF management are dealing with older and more complex cases [46, 47]; particularly when compared to earlier trials focussing on managing HF patients on an outpatient/ambulatory basis (the predominant model of care in many parts of the world [48]). Unfortunately, therefore, the relevance of previously effective management programmes in HF is likely to be eroded by an increasing proportion of patients with HF and multimorbidity with more challenging clinical priorities. Indeed, this may explain the neutral results of trials of more HF-centric interventions such as the COACH Study [49] and those applying remote monitoring techniques [50]. In comparison, positive results of home-based management when compared to clinic-based treatment in the WHICH? Trial [25] suggests a promising approach for those with HF and multimorbidity. To our knowledge, however, there are no definitive approaches to improve typically poor health outcomes that extend beyond standard HF management models of care.

The inherent complexity of managing multiple comorbid conditions is exacerbated by issues such as frailty, social isolation, impaired cognition and limited income that frequently negatively impact on sufferers of HF, who are typically elderly [51–53]. Although practical and disease-related issues are often closely interrelated [16,54–56], complexity is often overlooked, adversely affecting quality of life, hospital admission risk and survival [57–59]. Recent research reveals that it is these very complex, multimorbid or high-risk patients who stand to benefit most from home-based patient-centred management programmes [60]. From a health-cost perspective, the home-based approach to patient-centred management has been shown to be more both clinically beneficial (reduced hospital stay and prolonged survival) and cost-effective when compared to an equivalent specialist HF clinic in the head-to-head WHICH? Trial. Notably this trial specifically targeted older patients with HF and multimorbidity [61]. Taken together, these findings support the need for a paradigm shift — away from disease management, which by definition targets a specific primary disease (e.g. HF), to a more holistic approach, which considers each condition in the broader context of competing morbidities and seeks to design care in a way that optimises patient-centred outcomes (i.e., patient-centred care).

4.4.2. Coordinating care in the setting of multimorbidity in HF—Interventions addressing multimorbidity and clinical complexity in this population have the potential to reduce hospitalisations and prolong survival beyond that achieved by traditional disease management and transitional care programmes. The latter targets poor communication and poorly coordinated transitions at hospital discharge that contribute to negative health outcomes and increases the financial burden on the healthcare system (i.e., adverse events and increased hospitalisations) [62]. Transitional care is effective in older adults with HF who require complex care [63]. However, transitional care typically continues for at most 3-

months after hospital discharge, which risks readmission if self-care is not mastered and/or comorbid conditions are not stabilised during that period. Although interventions for specific disease combinations have been tested (e.g., HF and diabetes) [64–67], clinical guidelines integrating the care of multiple conditions are rare. [68]. Other approaches such as interdisciplinary primary care [69] and interdisciplinary teams for nursing home residents [70] are in the early phases of testing. Two promising interventions for multimorbidity are patient-centred medical homes [71] and Guided Care [72–74]; both of which have the potential to overcome the challenge of home-bound individuals accessing community resources [75]. Likewise, the effectiveness of physician house call programmes [76], as well home-support with a more diverse team such as the CAPABLE team (comprising a nurse, an occupational therapist and a handyman) are being evaluated [77,78].

4.4.3. An emphasis on self-care—Self-care important in any health condition, is particularly crucial for patients with complex illnesses and comorbidity. The seminal work in defining self-care in adults with chronic illness has been undertaken by Riegel and colleagues [79–81], who have conducted numerous studies aimed at understanding [82–86] and strengthening the ability of patients to perform self-care activities including adherence to medications and diet, as well as the detection and management of symptoms [87–89]. Encouragingly, a recent pilot study demonstrated that in a predominantly minority HF sample with significant multimorbidity, a tailored home-based intervention using motivational interviewing and skill-based education [87,89] achieved a statistically significant and clinically meaningful improvement in self-care that exceeded that of standard care [90,91]. Furthermore, hospitalisations unrelated to HF were less frequent in the group receiving the intervention [92]. Overall, there is good evidence to suggest that enhanced self-care can decrease symptom severity, improve health related quality of life (HRQoL), delay acute decompensation, and prevent hospitalisation in HF patients [93–95].

4.4.4. A carer-centred approach—Given that self-care may be particularly challenging for those HF patients with comorbid conditions such cognitive impairment [96], it is vital that the role of the family and other caregivers be recognised and supported. A recent systematic narrative review revealed that despite the pivotal role played by caregivers in the care of HF patients, their needs have not been clearly understood [97]. Three major areas of need identified were, 1) psychosocial support to maintain a sense of normalcy, 2) support with daily living, and 3) support navigating the healthcare system. Although health professionals agree that patient and caregiver uncertainty and unmet needs are major problems, they feel lacking in knowledge, opportunities, or have adequate support to improve the situation [98]. In order to improve outcomes for both caregivers and HF patients, it seems clear that an individualised, person and family-centred approach is required and must address issues arising both from HF and from multimorbidity. In addition, it is vital for future research to focus on how to optimally support and assist caregivers.

4.4.5. Applying case management in multimorbidity—Case management is a collaborative process used to assess, plan, implement, coordinate, monitor, and evaluate the services required to meet a patient's health and human service needs [99]. The case management process is characterised by communication, resource management, and

advocacy with a focus on promoting quality and cost-effective care. A key component of case management, as with other successful disease management strategies, is a post-discharge home visit to chronically ill, older adults who have complex social and environmental issues (e.g., social isolation, financial stress) that are rarely recognised and addressed in routine clinical care [57–59]. In addition to shifting the locus of control to the patient and assessing any residual signs of clinical instability, a post-discharge home visit permits a physical walk-through of the home with the patient, noting any environmental issues that would compromise safety, most notably entry sites and steps, bathroom areas and flooring (e.g. loose rugs that may require attention for those with physical frailty). At the same time, this visit allows the case manager to assess and support self-care abilities in a naturalistic environment; permitting them to tailor interventions to address the individual characteristics of the recipient [100], and focussing on skill rather than simply knowledge [87,89]. Additionally, including physiotherapy-based treatments may be beneficial as it has been recently shown that physiotherapy assists in falls prevention and reducing functional deficits in those with cardiovascular disease [101]. Specifically, aerobic or resistance training can assist to improve physical performance and HRQoL, and may increase the probability of older adults remaining independent [101,102], with home-based exercise programmes found to be as effective as supervised exercise programmes [103,104].

The fundamental role of the case manager (typically an experienced nurse with relevant post-graduate qualifications and excellent communication skills), is coordination and navigation, marshalling both personnel and resources needed to carry out required patient care activities [105]; this includes involving families and caregivers. The case manager is responsible for exchanging information among the various providers to help ensure that the patient's needs and preferences for health services and information are met [106]. Given the complexity and potential for competing priorities in this clinical setting, it is critical that the need for all therapies, especially those with risk for harm, be critically assessed. For example, polypharmacy is ubiquitous in this patient population and a process of “de-prescribing” should be considered. This may include weaning central nervous system-active medicines (benzodiazepines, opioids), corticosteroids, and even cardiovascular drugs (e.g. statins, beta-blockers) over a timeframe of weeks to months [107,108].

4.5. Step 5: Evaluate health outcomes well beyond acute hospitalisation and encompass all-cause events and a person-centred perspective in affected individuals

Despite an understandable focus on immediate and costly rebounds to hospital in the short-term (i.e. within 30-days) [109–112], there is a strong rationale for adopting a longer and more holistic perspective to reflect the entire patient journey. The classical description of the natural history of HF reinforces this point; periods of clinical instability are typically interspersed with periods of relative stability [113]. Clinical studies of disease management programmes often adopt singular endpoints (e.g. risk of re-hospitalisation) over a short period of time and/or confine analyses to those events relating to the syndrome (i.e., HF specific). However, such an approach is limited from both a patient and health service perspective because there is clear potential for longer survival free from all-cause hospitalisation and with improved HRQoL. In simple terms, restricting follow-up to a short-time period (e.g. 30-days to 3-months) belies the complex interplay between short-term and

long-term stability with respect to the potential benefit of more intensive management. For example, a “therapeutic” early readmission may result in fewer hospital days and better quality of life over the ensuing 12-month period.

These considerations do not undermine the importance of monitoring short-term outcomes; particularly when one considers that 20–25% of HF patients are readmitted within 30-days of hospital discharge [13]. Due to the costs of hospitalisation [10], scrutiny of readmissions has intensified in many countries. In this regard, multimorbidity has been identified as playing a critical role in driving both early and late readmissions in HF [18]. Indeed, two-thirds of patients readmitted within 30-days are hospitalised for a condition other than HF [13]. On this basis, there is a strong rationale to examine the overall pattern of morbidity and mortality (i.e. on an all-cause basis) over the longer-term; particularly when considering the pattern of multimorbidity present (derived from systematic profiling). Concurrently, the desire to involve patients in setting their own goals provides a strong argument for evaluating the relative success of management from a person-centred perspective, such as patient-reported HRQoL and satisfaction with health service delivery.

Fig. 2: Pragmatic interpretation of how the 5 key recommendations for improving health outcomes in HF and multimorbidity might be applied on a differential basis, illustrates how the five steps outlined above might be applied to improve health outcomes in this increasingly common patient cohort; as suggested by this figure, patients with HF and multimorbidity now represent the majority of those hospitalised with HF. However, future research is required to determine how to apply these steps in a cost-efficient manner (including the use of information technology to facilitate profiling and communication strategies) and, to determine if the steps do indeed achieve better health outcomes in a range of health care settings.

5. Discussion

There is overwhelming evidence that multimorbidity in HF is a growing problem within an ageing population of HF patients. For example, according to U.S. Census Bureau projections, between 2000 and 2030, those 65 years and over are expected to increase from 34.8 million to over 70.3 million. In addition, those aged 85 years are the fastest growing age group, and the number of 85+ year olds in the US is expected to increase fivefold by 2050 [114]. Since approximately 75% of older Americans have two or more chronic conditions, the number of patients with HF and multimorbidity will inevitably continue to rise [115]. Not only is multimorbidity becoming more common, it is associated with poor health outcomes that potentially defy disease management strategies developed for younger and less complex cases of HF. As such, without pro-active management strategies to stabilise the clinical status of affected individuals in the longer-term, progression to geriatric syndromes such as falls, worsening renal function, and repetitive hospitalisations that ultimately lead to disability, frailty, loss of independence, and death will continue to occur with accelerating frequency [114,115].

The potential for an increasing pool of patients with HF and multimorbidity to generate an unsustainable wave of patients with complex health care needs that are currently poorly

served by existing health systems cannot be over-stated. As previously suggested by our group [15], reducing hospitalisations for any particular problem (e.g. acute decompensated HF) has the potential for avoiding deleterious consequences of hospitalisation itself, including delirium, iatrogenic illness, infections, deconditioning, sarcopenia, and increased falls risk. Recognising and addressing these risks and potential adverse effects is critical for reducing disability and optimising long-term health outcomes. For example, sarcopenia represents an increasingly important health problem in older adults [116]. For the HF patient, an initial hospital admission with associated bed-rest is likely to exacerbate underlying muscle dysfunction and wasting [117]; increasing the risk of recurrent hospitalisation in the absence of proactive mobilisation and occupational therapy [118,119]. Similarly, catastrophic fall risk increases exponentially in the hospital setting; something that is routinely observed in the clinical management of older patients with HF and multimorbidity. Therefore, more pro-active efforts to minimise age-related physical decline and dysfunction are necessary [120].

In writing this position paper, we explicitly acknowledge the inherent limitations of our review of the literature relating to HF and multimorbidity in respect to a predominant focus on co-morbidity as opposed to multimorbid interactions (the latter reflecting the limitations of the literature in this regard). The prevalence and influence of specific conditions (including the ten conditions of specific interest) will undoubtedly vary within different HF populations. We have made no distinction between HF with reduced or preserved ejection fraction. At the same time, we have not focused on the most common antecedents of HF (hypertension and ischaemic heart disease) as we believe these are routinely addressed in the majority of patients with HF. This paper is not a guideline or a systematic review. However, we have intentionally focussed on providing a framework of clinical actions rather than specific recommendations for clinical management; as emphasised repeatedly, management needs to be individualised while considering the type of information provided in Supplementary Table 1.

As emphasised throughout this position paper, any approach to the complex issues engendered by an increasing number of individuals with HF and multimorbidity requires an overarching, strategic approach. Our clinical framework for action, comprising the five key steps of ARISE-HF, can be best viewed through the prism of a previously published policy framework (and overarching goals) for improving health outcomes and HRQoL in individuals with multimorbidity [121–123]:

- Foster health care and public health system changes to improve the health of with HF and multimorbidity. This includes developing evidence-supported models to improve care coordination, defining appropriate health care outcomes and providing incentives to make positive changes to the health care system.
- Facilitate self-care, wherever possible, with an equal emphasis on facilitating home and community-based services.
- Provide better tools, strategies and information to health professionals directly managing individuals with multimorbidity so they can improve the effectiveness of care delivery and subsequent health out-comes.

- Undertake health services research to fill critical gaps in our understanding of multimorbidity in HF with an emphasis on clinical, community, and patient-centred studies that seek to develop cost-effective models of care.

In the future, we anticipate a greater focus on managing multimorbidity in HF in clinical practice guidelines but with a far greater emphasis on principles of individualised management rather than specific instructions. We emphasise, therefore, that this clinical framework, generated from a diverse collection of health professionals with practical expertise in the management of patients with multimorbidity, complements existing HF guidelines [124,125]. Our future challenge is to determine how best to incorporate what we have proposed into clinical practice and to demonstrate that it does indeed, as we expect, improve health outcomes in this growing patient population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

SS and MJC are supported by the National Health and Medical Research Council of Australia (1041796 and 1032934). WSW is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number U54-GM104941. The authors have stated that they have no relationships relevant to the contents of this paper to disclose.

References

1. Robert Wood Johnson Foundation. Chronic Care: Making the Case for Ongoing Care. Robert Wood Johnson Foundation; 2010.
2. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis.* 2013; 10:E65. [PubMed: 23618545]
3. Centers for Medicare & Medicaid Services. Chronic conditions Among Medicare Beneficiaries. Chart Book; Baltimore, MD: 2011.
4. Lochner KA, Cox CS. Prevalence of multiple chronic conditions among Medicare beneficiaries, United States, 2010. *Prev Chronic Dis.* 2013; 10:E61. [PubMed: 23618541]
5. Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. *Med J Aust.* 2008; 189(2):72–77. [PubMed: 18637770]
6. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract.* 2008; 14(Suppl. 1):28–32. [PubMed: 18949641]
7. Longman JM, Rolfe M, Passey MD, Heathcote KE, Ewald DP, Dunn T, et al. Frequent hospital admission of older people with chronic disease: a cross-sectional survey with telephone follow-up and data linkage. *BMC Health Serv Res.* 2012; 12:373. [PubMed: 23110342]
8. Salive ME. Multimorbidity in older adults. *Epidemiol Rev.* 2013; 35:75–83. [PubMed: 23372025]
9. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. *J Am Coll Cardiol.* 2003; 42(7):1226–1233. [PubMed: 14522486]
10. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail.* 2013; 6(3):606–619. [PubMed: 23616602]
11. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med.* 2009; 360(14):1418–1428. [PubMed: 19339721]
12. Bradley EH, Curry LA, Krumholz HM. Strategies to reduce heart failure readmissions. *JAMA.* 2014; 311(11):1160.

13. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA*. 2013; 309(4):355–363. [PubMed: 23340637]
14. Chong VH, Singh J, Parry H, Saunders J, Chowdhury F, Mancini DM, et al. Management of non-cardiac comorbidities in chronic heart failure. *Cardiovasc Ther*. 2015; 33(5):300–315. [PubMed: 26108139]
15. Stewart S, Riegel B, Thompson DR. Addressing the conundrum of multimorbidity in heart failure: do we need a more strategic approach to improve health outcomes? *Eur J Cardiovasc Nurs*. 2016; 15(1):4–7. [PubMed: 26362926]
16. Triposkiadis FK, Skoularigis J. Prevalence and importance of comorbidities in patients with heart failure. *Curr Heart Fail Rep*. 2012; 9(4):354–362. [PubMed: 22918666]
17. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition — multimorbidity. *JAMA*. 2012; 307(23):2493–2494. [PubMed: 22797447]
18. Foraker RE, Rose KM, Suchindran CM, Chang PP, McNeill AM, Rosamond WD. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: atherosclerosis risk in communities cohort (1987 to 2004). *Circ Heart Fail*. 2011; 4(3):308–316. [PubMed: 21430286]
19. Lee CS, Chien CV, Bidwell JT, Gelow JM, Denfeld QE, Creber R Masterson, et al. Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample. *BMC Cardiovasc Disord*. 2014; 14:73. [PubMed: 24898986]
20. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2012; 33(14):1787–1847. [PubMed: 22611136]
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013; 128(16):1810–1852. [PubMed: 23741057]
22. Whitty JA, Stewart S, Carrington MJ, Calderone A, Marwick T, Horowitz JD, et al. Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: findings from the Which? trial. *PLoS One*. 2013; 8(3):e58347. [PubMed: 23505491]
23. National Heart Foundation of Australia. *Multidisciplinary Care for People with Chronic Heart Failure. Principles and Recommendations for Best Practice*. 2010
24. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. *Lancet*. 2015; 385(9970):774–784. [PubMed: 25752180]
25. Stewart S, Carrington MJ, Marwick TH, Davidson PM, Macdonald P, Horowitz JD, et al. Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial. *J Am Coll Cardiol*. 2012; 60(14):1239–1248. [PubMed: 23017533]
26. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. *Lancet*. 1999; 354(9184):1077–1083. [PubMed: 10509499]
27. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA, AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association. American College of Cardiology, and US Department of Health and Human Services. *Circulation*. 2014; 130(18):1662–1667. [PubMed: 25212466]
28. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, et al. Randomised controlled trial of specialist nurse intervention in heart failure. *BMJ*. 2001; 323(7315):715–718. [PubMed: 11576977]

29. Riegel B, Carlson B, Glaser D, Hoagland P. Which patients with heart failure respond best to multidisciplinary disease management? *J Card Fail.* 2000; 6(4):290–299. [PubMed: 11145753]
30. Riegel B, Carlson B, Glaser D, Romero T. Randomized controlled trial of telephone case management in Hispanics of Mexican origin with heart failure. *J Card Fail.* 2006; 12(3):211–219. [PubMed: 16624687]
31. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure(see comment). *Arch Intern Med.* 2002; 162(6):705–712. [PubMed: 11911726]
32. Ara S. A literature review of cardiovascular disease management programs in managed care populations. *J Manag Care Pharm.* 2004; 10(4):326–344. [PubMed: 15298531]
33. Gohler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, et al. A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. *J Card Fail.* 2006; 12(7):554–567. [PubMed: 16952790]
34. Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. *Eur Heart J.* 2004; 25(18):1570–1595. [PubMed: 15351157]
35. Leppin AL, Gionfriddo MR, Kessler M, Brito JP, Mair FS, Gallacher K, et al. Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials. *JAMA Intern Med.* 2014; 174(7):1095–1107. [PubMed: 24820131]
36. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. *Am J Med.* 2001; 110(5):378–384. [PubMed: 11286953]
37. Ofman JJ, Badamgarav E, Henning JM, Knight K, Gano AD Jr, Levan RK, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. *Am J Med.* 2004; 117(3):182–192. [PubMed: 15300966]
38. Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. *Eur J Heart Fail.* 2005; 7(7):1133–1144. [PubMed: 16198629]
39. Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. *Trials.* 2011; 12:194. [PubMed: 21846340]
40. Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. *Am Heart J.* 2005; 149(4):722–729. [PubMed: 15990759]
41. Kociol RD, Liang L, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW, et al. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. *Am Heart J.* 2013; 165(6):987–994 (e1). [PubMed: 23708171]
42. Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray JJ, Naylor MD, et al. What works in chronic care management: the case of heart failure. *Health Aff.* 2009; 28(1):179–189.
43. Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The increasing burden and complexity of multimorbidity. *BMC Public Health.* 2015; 15:415. [PubMed: 25903064]
44. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital Discharge Registry 1988 to 2000. *Eur Heart J.* 2004; 25(4):300–307. [PubMed: 14984918]
45. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? *Heart.* 2003; 89(1):49–53. [PubMed: 12482791]
46. Driscoll A, Worrall-Carter L, Hare DL, Davidson PM, Riegel B, Tonkin A, et al. Evidence-based chronic heart failure management programs: reality or myth? *Qual Saf Health Care.* 2009; 18(6):450–455. [PubMed: 19955456]
47. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol.* 2004; 44(4):810–819. [PubMed: 15312864]

48. Krum H, Driscoll A. Management of heart failure. *Med J Aust.* 2013; 199(5):334–339. [PubMed: 23992190]
49. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart failure (COACH). *Arch Intern Med.* 2008; 168(3):316–324. [PubMed: 18268174]
50. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. *N Engl J Med.* 2010; 363(24):2301–2309. [PubMed: 21080835]
51. Freedland KE, Carney RM. Psychosocial considerations in elderly patients with heart failure. *Clin Geriatr Med.* 2000; 16(3):649–661. [PubMed: 10918652]
52. Kerzner R, Rich MW. Management of heart failure in the elderly. *Curr Cardiol Rep.* 2003; 5(3): 223–228. [PubMed: 12691641]
53. Norberg EB, Boman K, Lofgren B, Brannstrom M. Occupational performance and strategies for managing daily life among the elderly with heart failure. *Scand J Occup Ther.* 2014; 21(5):392–399. [PubMed: 24878004]
54. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol.* 2012; 59(11):998–1005. [PubMed: 22402071]
55. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. *Heart.* 2007; 93(6): 665–671. [PubMed: 16488925]
56. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. *Ann Fam Med.* 2009; 7(4):357–363. [PubMed: 19597174]
57. Moraska AR, Chamberlain AM, Shah ND, Vickers KS, Rummans TA, Dunlay SM, et al. Depression, healthcare utilization, and death in heart failure: a community study. *Circ Heart Fail.* 2013; 6(3):387–394. [PubMed: 23512984]
58. Radhakrishnan K, Bowles K, Hanlon A, Topaz M, Chittams J. A retrospective study on patient characteristics and telehealth alerts indicative of key medical events for heart failure patients at a home health agency. *Telemed J E Health.* 2013; 19(9):664–670. [PubMed: 23808888]
59. Retrum JH, Boggs J, Hersh A, Wright L, Main DS, Magid DJ, et al. Patient-identified factors related to heart failure readmissions. *Circ Cardiovasc Qual Outcomes.* 2013; 6(2):171–177. [PubMed: 23386663]
60. Stewart, S., Wiley, J., Chan, YK., Ball, J., Thompson, DR., Carrington, MJ. Late-Breaking Clinical Trial Presentation. European Society of Cardiology Scientific Congress; London, UK: 2015. Prolonged event-free survival in more complex cases of heart disease: outcome data from 1,226 patients from 3 randomised trials of nurse-led, multidisciplinary home-based intervention.
61. Stewart S, Carrington MJ, Horowitz JD, Marwick TH, Newton PJ, Davidson PM, et al. Prolonged impact of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort. *Int J Cardiol.* 2014; 174(3):600–610. [PubMed: 24825029]
62. Sweeney L, Halpert A, Waranoff J. Patient-centered management of complex patients can reduce costs without shortening life. *Am J Manag Care.* 2007; 13(2):84–92. [PubMed: 17286528]
63. Naylor MD, Brooten DA, Campbell RL, Maislin G, McCauley KM, Schwartz JS. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial. *J Am Geriatr Soc.* 2004; 52(5):675–684. [PubMed: 15086645]
64. Dunbar SB, Reilly CM, Gary R, Higgins MK, Culler S, Butts B, et al. Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. *J Card Fail.* 2015; 21(9):719–729. [PubMed: 26028261]
65. Granger BB, Ekman I, Hernandez AF, Sawyer T, Bowers MT, DeWald TA, et al. Results of the chronic heart failure intervention to improve MEducation adherence study: a randomized intervention in high-risk patients. *Am Heart J.* 2015; 169(4):539–548. [PubMed: 25819861]
66. Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, et al. Tools for economic analysis of patient management interventions in heart failure cost-effectiveness model: a web-based

- program designed to evaluate the cost-effectiveness of disease management programs in heart failure. *Am Heart J.* 2015; 170(5):951–960. [PubMed: 26542504]
67. Reilly CM, Butler J, Culler SD, Gary RA, Higgins M, Schindler P, et al. An economic evaluation of a self-care intervention in persons with heart failure and diabetes. *J Card Fail.* 2015; 21(9):730–737. [PubMed: 26164214]
 68. Pauly MV. Accountable care organizations and kidney disease care: health reform innovation or more same-old, same-old? *Am J Kidney Dis.* 2012; 60(4):524–529. [PubMed: 22800855]
 69. Metzeltin SF, van Rossum E, de Witte LP, Ambergen AW, Hobma SO, Sipers W, et al. Effectiveness of interdisciplinary primary care approach to reduce disability in community dwelling frail older people: cluster randomised controlled trial. *BMJ.* 2013; 347:f5264. [PubMed: 24022033]
 70. Rosenberg T. Acute hospital use, nursing home placement, and mortality in a frail community-dwelling cohort managed with primary integrated interdisciplinary elder care at home. *J Am Geriatr Soc.* 2012; 60(7):1340–1346. [PubMed: 22694020]
 71. Page TF, Amofah SA, McCann S, Rivo J, Varghese A, James T, et al. Care Management Medical Home Center model: preliminary results of a patient-centered approach to improving care quality for diabetic patients. *Health Promot Pract.* 2015; 16(4):609–616. [PubMed: 25564454]
 72. Boulton C, Reider L, Leff B, Frick KD, Boyd CM, Wolff JL, et al. The effect of guided care teams on the use of health services: results from a cluster-randomized controlled trial. *Arch Intern Med.* 2011; 171(5):460–466. [PubMed: 21403043]
 73. Boyd CM, Boulton C, Shadmi E, Leff B, Brager R, Dunbar L, et al. Guided care for multimorbid older adults. *Gerontologist.* 2007; 47(5):697–704. [PubMed: 17989412]
 74. Leff B, Reider L, Frick KD, Scharfstein DO, Boyd CM, Frey K, et al. Guided care and the cost of complex healthcare: a preliminary report. *Am J Manag Care.* 2009; 15(8):555–559. [PubMed: 19670959]
 75. Hollingsworth JM, Saint S, Hayward RA, Rogers MA, Zhang L, Miller DC. Specialty care and the patient-centered medical home. *Med Care.* 2011; 49(1):4–9. [PubMed: 20966777]
 76. Centers for Medicare and Medicaid Services. *Services Centers for Medicare and Medicaid Services. USA: 2014. Independence at Home Demonstration.*
 77. Szanton SL, Roth J, Nkimbeng M, Savage J, Klimmek R. Improving unsafe environments to support aging independence with limited resources. *Nurs Clin N Am.* 2014; 49(2):133–145.
 78. Szanton SL, Wolff JW, Leff B, Thorpe RJ, Tanner EK, Boyd C, et al. CAPABLE trial: a randomized controlled trial of nurse, occupational therapist and handyman to reduce disability among older adults: rationale and design. *Contemp Clin Trials.* 2014; 38(1):102–112. [PubMed: 24685996]
 79. Riegel B, Dickson VV. A situation-specific theory of heart failure self-care. *J Cardiovasc Nurs.* 2008; 23(3):190–196. [PubMed: 18437059]
 80. Riegel B, Dickson VV, Faulkner KM. The situation-specific theory of heart failure self-care: revised and updated. *J Cardiovasc Nurs.* 2015 [Epub ahead of print].
 81. Riegel B, Jaarsma T, Stromberg A. A middle-range theory of self-care of chronic illness, ANS *Adv. Nurs Sci.* 2012; 35(3):194–204.
 82. Dickson VV, Buck H, Riegel B. Multiple comorbid conditions challenge heart failure self-care by decreasing self-efficacy. *Nurs Res.* 2013; 62(1):2–9. [PubMed: 23052421]
 83. Dickson VV, Deatrick JA, Riegel B. A typology of heart failure self-care management in non-elders. *Eur J Cardiovasc Nurs.* 2008; 7(3):171–181. [PubMed: 18178132]
 84. Dickson VV, Tkacs N, Riegel B. Cognitive influences on self-care decision making in persons with heart failure. *Am Heart J.* 2007; 154(3):424–431. [PubMed: 17719284]
 85. Riegel B, Carlson B. Facilitators and barriers to heart failure self-care. *Patient Educ Couns.* 2002; 46:287–295. [PubMed: 11932128]
 86. Riegel B, Lee CS, Albert N, Lennie T, Chung M, Song EK, et al. From novice to expert: confidence and activity status determine heart failure self-care performance. *Nurs Res.* 2011; 60(2):132–138. [PubMed: 21317825]

87. Dickson VV, Melkus GD, Katz S, Levine-Wong A, Dillworth J, Cleland CM, et al. Building skill in heart failure self-care among community dwelling older adults: results of a pilot study. *Patient Educ Couns.* 2014; 96(2):188–196. [PubMed: 24910422]
88. Dickson VV, Nocella J, Yoon HW, Hammer M, Melkus GD, Chyun D. Cardiovascular disease self-care interventions. *Nurs Res Pract.* 2013; 2013:407608. [PubMed: 24223305]
89. Dickson VV, Riegel B. Are we teaching what patients need to know? Building skills in heart failure self-care. *Heart Lung.* 2009; 38(3):253–261. [PubMed: 19486796]
90. Creber, R Masterson, Patey, M., Dickson, VV., DeCesaris, M., Riegel, B. Motivational Interviewing Tailored Interventions for Heart Failure (MITI-HF): study design and methods. *Contemp Clin Trials.* 2015; 41:62–68. [PubMed: 25559913]
91. Creber, R Masterson, Patey, M., Lee, CS., Kuan, A., Riegel, B. Motivational Interviewing Tailored Interventions for Heart Failure (MITI-HF): randomized controlled trial. *Patient Educ Couns.* 2015 [Epub ahead of print].
92. Creber, R Masterson, Patey, M., Lee, CS., Kuan, A., Jurgens, C., Riegel, B. Motivational interviewing to improve self-care for patients with chronic heart failure: MITI-HF randomized controlled trial. *Patient Educ Couns.* 2015 [Epub ahead of print].
93. Lee CS, Carlson B, Riegel B. Heart failure self-care improves economic outcomes, but only when self-care confidence is high. *J Card Fail.* 2007; 13(6):S75.
94. Lee CS, Moser DK, Lennie TA, Riegel B. Event-free survival in adults with heart failure who engage in self-care management. *Heart Lung.* 2011; 40(1):12–20. [PubMed: 20561885]
95. Lee CS, Moser DK, Lennie TA, Tkacs NC, Margulies KB, Riegel B. Biomarkers of myocardial stress and systemic inflammation in patients who engage in heart failure self-care management. *J Cardiovasc Nurs.* 2011; 26(4):321–328. [PubMed: 21263344]
96. Dickson VV, Buck H, Riegel B. A qualitative meta-analysis of heart failure self-care practices among individuals with multiple comorbid conditions. *J Card Fail.* 2011; 17(5):413–419. [PubMed: 21549299]
97. Doherty LC, Fitzsimons D, McIlfratrick SJ. Carers' needs in advanced heart failure: a systematic narrative review. *Eur J Cardiovasc Nurs.* 2015 [Epub ahead of print].
98. Browne S, Macdonald S, May CR, Macleod U, Mair FS. Patient, carer and professional perspectives on barriers and facilitators to quality care in advanced heart failure. *PLoS One.* 2014; 9(3):e93288. [PubMed: 24676421]
99. Commission for Case Manager Certification. 2014. [September 27, 2014]. Available from: <http://ccmcertification.org/>
100. Beck C, McSweeney JC, Richards KC, Roberson PK, Tsai PF, Souder E. Challenges in tailored intervention research. *Nurs Outlook.* 2010; 58(2):104–110. [PubMed: 20362779]
101. Gary R. Evaluation of frailty in older adults with cardiovascular disease: incorporating physical performance measures. *J Cardiovasc Nurs.* 2012; 27(2):120–131. [PubMed: 22334147]
102. Knocke A. Program description: physical therapy in a heart failure clinic. *Cardiopulm. Phys Ther J.* 2012; 23(3):46–48.
103. Taylor RS, Dalal H, Jolly K, Moxham T, Zawada A. Home-based versus centre-based cardiac rehabilitation. *Cochrane Database Syst Rev.* 2010; 1:CD007130.
104. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ.* 2010; 340:b5631. [PubMed: 20085991]
105. McDonald, K., Sundaram, V., Bravada, D., Lewis, R., Lin, N., Kraft, S., et al. In closing the quality gap: a critical analysis of quality improvement strategies technical review 9, 290-02-0017) Prepared by: Stanford-UCSF Evidence-Based Practice Center. Agency for Healthcare Research and Quality; Rockville, MD: 2007. Care coordination.
106. National Quality Forum (NQF). Preferred Practices and Performance Measures for Measuring and Reporting Care Coordination: A Consensus Report. Washington, DC: 2010.
107. Frank C, Weir E. Deprescribing for older patients. *CMAJ.* 2014; 186(18):1369–1376. [PubMed: 25183716]
108. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. *Drugs Aging.* 2013; 30(10):793–807. [PubMed: 23912674]

109. Allen LA, Tomic KE Smoyer, Smith DM, Wilson KL, Agodoa I. Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. *Circ Heart Fail.* 2012; 5(6):672–679. [PubMed: 23072736]
110. Bradley EH, Curry L, Horwitz LI, Sipsma H, Wang Y, Walsh MN, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. *Circ Cardiovasc Qual Outcomes.* 2013; 6(4):444–450. [PubMed: 23861483]
111. Hernandez MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, et al. Predictors of 30-day readmission in patients hospitalized with decompensated heart failure. *Clin Cardiol.* 2013; 36(9):542–547. [PubMed: 23929763]
112. Wexler R. Early physician follow-up and 30-day readmission among older patients with heart failure. *JAMA.* 2010; 304(7):743. (author reply -4). [PubMed: 20716735]
113. Goodlin SJ. Palliative care in congestive heart failure. *J Am Coll Cardiol.* 2009; 54(5):386–396. [PubMed: 19628112]
114. Ironside PM, Tagliareni ME, McLaughlin B, King E, Mengel A. Fostering geriatrics in associate degree nursing education: an assessment of current curricula and clinical experiences. *J Nurs Educ.* 2010; 49(5):246–252. [PubMed: 20210290]
115. Agency for Healthcare Research and Quality. *Developing Tools and Data for Research and Policymaking.* 2012
116. Wall BT, Dirks ML, van Loon LJ. Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. *Ageing Res Rev.* 2013; 12(4):898–906. [PubMed: 23948422]
117. Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *FASEB J.* 2005; 19(3):422–424. [PubMed: 15596483]
118. Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. *JAMA.* 2008; 300(14):1685–1690. [PubMed: 18840842]
119. Stall N. Tackling immobility in hospitalized seniors. *CMAJ.* 2012; 184(15):1666–1667. [PubMed: 22988157]
120. Brown-O'Hara T. Geriatric syndromes and their implications for nursing. *Nursing.* 2013; 1–3
121. Parekh AK, Goodman RA, Gordon C, Koh HK. The HHS, Interagency workgroup on multiple chronic conditions. *managing multiple chronic conditions: a strategic framework for improving health outcomes and quality of life.* Public Health Rep. 2011; 126(4):460–471. [PubMed: 21800741]
122. Parekh AK, Kronick R, Tavenner M. Optimizing health for persons with multiple chronic conditions. *JAMA.* 2014; 312(12):1199–1200. [PubMed: 25133982]
123. US Department of Health and Human Services. *Multiple Chronic Conditions — A Strategic Framework: Optimum Health and Quality of Life for Individuals with Multiple Chronic Conditions.* Washington, DC: 2010.
124. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart failure 2012 of the European Society Of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail.* 2012; 14(8):803–869. [PubMed: 22828712]
125. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management Of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol.* 2013; 62(16):e147–e239. [PubMed: 23747642]
126. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. *Med J Aust.* 2010; 193(9):525–532. [PubMed: 21034387]
127. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on pacemaker implantation). *J Am Coll Cardiol.* 1998; 31(5):1175–1209. [PubMed: 9562026]

128. Doerflinger, DMC. Mental Status Assessment in Older Adults: Montreal Cognitive Assessment: MoCA Version 7.1 (Original Version). Virginia: 2012.
129. Lowe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. *J Affect Disord.* 2010; 122(1–2):86–95. [PubMed: 19616305]
130. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol.* 2006; 48(8):1527–1537. [PubMed: 17045884]
131. Zamora E, Lupon J, Vila J, Urrutia A, de Antonio M, Sanz H, et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockroftgault formulas. *J Am Coll Cardiol.* 2012; 59(19):1709–1715. [PubMed: 22554602]
132. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J.* 2004; 23(6):932–946. [PubMed: 15219010]
133. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. *Circulation.* 2010; 122(4): 385–393. [PubMed: 20660814]
134. Sharma S, Mather P, Efird JT, Kahn D, Cheema M, Rubin S, et al. Photoplethysmographic signal to screen sleep-disordered breathing in hospitalized heart failure patients: feasibility of a prospective clinical pathway. *JACC Heart Fail.* 2015; 3(9):725–731. [PubMed: 26362449]




Fig. 1. A conundrum of multimorbidity in HF (reproduced with permission).




Fig. 2.
Pragmatic interpretation of 5 key recommendations.

Table 1

Search terms used to identify published reports focussing on HF and the ten pre-specified concurrent conditions with total citations found.

Comorbidity	Search terms	Citations
Anaemia	Anaemia OR anemia AND heart failure AND Management OR treatment	303
Sleep disordered breathing	Sleep disordered breathing OR obstructive sleep apnoea OR central sleep apnoea AND heart failure AND management OR treatment	179
Respiratory disease	Respiratory disease OR dyspnoea OR chronic obstructive pulmonary disease AND heart failure AND management OR treatment	817
Diabetes mellitus	Diabetes mellitus AND heart failure AND management OR treatment	486
Depression	Depression AND heart failure AND management OR treatment	387
Renal impairment	Renal impairment OR renal dysfunction AND heart failure AND management OR treatment	322
Cognitive impairment	Cognitive impairment AND heart failure AND management OR treatment	74
Musculoskeletal disorders	Musculoskeletal disorders OR osteoporosis OR osteopenia OR osteoarthritis OR rheumatoid arthritis AND heart failure AND management OR treatment	105
Arrhythmias	Arrhythmias OR atrial fibrillation AND heart failure AND management OR treatment	814
Thyroid disease	Thyroid disease OR hyperthyroidism OR hypothyroidism AND heart failure AND management OR treatment	86

Table 2

Suggested framework for documenting and quantifying multimorbidity in HF.

Co-morbidity	Data source and determination	Definition/deficit threshold
Anaemia	Full blood examination during hospital admission	Serum Hb level \leq 130 (women)/ \leq 120 g/L (men) [126,127]
Atrial and ventricular arrhythmias	Review of medical notes plus review of prescribed pharmacotherapy at discharge If high clinical suspicion of undiagnosed arrhythmia - 12-lead ECG, inpatient telemetry or extended ECG Holter monitoring	Confirmation of AF, other atrial arrhythmias, 2nd or 3rd degree heart block, VT/VF with prescription of anti-arrhythmic therapy or pacemaker/defibrillator device [128]
Cognitive impairment/dementia	Assessed via Montreal Cognitive Assessment (MoCA) tool prior to hospital discharge by trained personnel	Documented diagnosis of dementia or MoCA score \leq 26 out of a maximal possible score of 30 [129]
Depression/anxiety	Assessed via PQ-2 [130] questionnaire prior to hospital discharge by trained personnel plus review of medical notes and prescribed pharmacotherapy at discharge. If positive, apply more comprehensive tool (e.g. HADS) [131]	Positive response to depressive symptoms and/or confirmed diagnosis (with active anti-depressant/ anxiolytic) of depression or anxiety
Diabetes and metabolic disorders	Review of medical notes and prescribed pharmacotherapy at discharge Calculation of body mass index (BMI) If high clinical suspicion of underlying diabetes HbA1c and/or glucose tolerance tests	Documented diagnosis of Type 2 Diabetes or obesity BMI \geq 30 kg/m ² plus dyslipidaemia and/or hypertension (metabolic syndrome)
Musculoskeletal disorders	Review of medical notes and prescribed pharmacotherapy at discharge Frailty test with hand-grip manometer, gait speed, six-minute walk test, and Short Physical Performance Battery including static balance, gait speed and getting in and out of a chair [101]	Documented diagnosis of arthritis, osteoporosis, gout or any other musculoskeletal condition requiring active therapy (e.g. anti-inflammatory or analgesia)
Renal impairment	Electrolytes and renal function obtained during hospital admission Calculation of body mass index	Estimated glomerular filtration rate \leq 60 mL/min/1.73 m ² [132]
Respiratory disease	Review of medical notes and prescribed pharmacotherapy at discharge If high clinical suspicion of underlying respiratory disease - formal lung function tests	Lung function confirmation of COPD, asthma and/or other chronic pulmonary condition requiring active treatment [133]
Thyroid disease	Review of medical notes and prescribed pharmacotherapy at discharge If high clinical suspicion of, or historical lack of screening, perform thyroid function tests (including thyroid stimulating hormone levels) at hospital admission	Documented hyper/ hypothyroidism based on according to national standards with associated anti-thyroid or thyroxine replacement therapy [134]
Sleep disorders	Review of medical notes and prescribed sleep support device. If high clinical suspicion of sleep disordered breathing perform formal sleep studies Use of a screening questionnaire in hospital to identify those with sleep-disordered breathing (135)	Documented diagnosis of obstructive or central sleep disordered breathing